BCM
IBB icon

BlueCrest Capital Management’s iShares Biotechnology ETF IBB Stock Holding History

BlueCrest Capital Management’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$475K Buy
+2,500
New +$430K 0.02% 249
2015
Q4 		– Sell
-9,000
Closed -$910K – 1070
2015
Q3 		$910K Buy
+9,000
New +$1.08M 0.03% 467

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $22.8B AUM 28.56% 1-Year Est. Return

BlueCrest Capital Management's IBB Position: Q4 2019 in Review

BlueCrest Capital Management sold out of iShares Biotechnology ETF (IBB) in Q4 2019, closing a stake of 14,967 shares — an estimated $1.49M sold.

BlueCrest Capital Management first reported a position in IBB in Q3 2015 and held it in 12 quarters. The position peaked at $27.7M in Q3 2017. 710 funds tracked by Wall St. Rank hold IBB as of Q4 2019.

  • BlueCrest Capital Management reported no remaining iShares Biotechnology ETF position as of Q4 2019 after selling out during the quarter.
  • BlueCrest Capital Management sold 14,967 iShares Biotechnology ETF shares in Q4 2019, an estimated $1.49M.
  • BlueCrest Capital Management first reported a position in iShares Biotechnology ETF in Q3 2015 and held it in 12 quarters.
  • BlueCrest Capital Management's iShares Biotechnology ETF position peaked at $27.7M in Q3 2017.
  • 710 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q4 2019.

Based on BlueCrest Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.